Insider Transactions in Q4 2023 at Deciphera Pharmaceuticals, Inc. (DCPH)
Insider Transaction List (Q4 2023)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Dec 13
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,792
-2.81%
|
$41,880
$15.37 P/Share
|
|
Dec 13
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,727
-3.39%
|
$25,905
$15.37 P/Share
|
|
Dec 13
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,662
-3.09%
|
$24,930
$15.37 P/Share
|
|
Dec 13
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,792
-3.92%
|
$41,880
$15.37 P/Share
|
|
Dec 13
2023
|
Steven L. Hoerter President and CEO |
SELL
Open market or private sale
|
Direct |
30,664
-29.65%
|
$459,960
$15.37 P/Share
|
|
Dec 12
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,244
+7.67%
|
-
|
|
Dec 12
2023
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,576
+9.85%
|
-
|
|
Dec 12
2023
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,576
+9.38%
|
-
|
|
Dec 12
2023
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,244
+10.36%
|
-
|
|
Dec 12
2023
|
Steven L. Hoerter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+37.67%
|
-
|
|
Nov 30
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
17,801
-28.15%
|
$213,612
$12.57 P/Share
|
|
Oct 30
2023
|
Daniel C. Martin Chief Commercial Officer |
SELL
Open market or private sale
|
Direct |
1,407
-2.19%
|
$16,884
$12.02 P/Share
|
|
Oct 30
2023
|
Jama Pitman SVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,407
-2.83%
|
$16,884
$12.02 P/Share
|
|
Oct 30
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,360
-2.54%
|
$28,320
$12.02 P/Share
|
|
Oct 30
2023
|
Steven L. Hoerter President and CEO |
SELL
Open market or private sale
|
Direct |
21,573
-34.52%
|
$258,876
$12.02 P/Share
|
|
Oct 30
2023
|
Thomas Patrick Kelly Chief Financial Officer |
SELL
Open market or private sale
|
Direct |
2,316
-3.54%
|
$27,792
$12.02 P/Share
|
|
Oct 28
2023
|
Daniel C. Martin Chief Commercial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,576
+7.98%
|
-
|
|
Oct 28
2023
|
Jama Pitman SVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
5,576
+10.09%
|
-
|
|
Oct 28
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,244
+8.14%
|
-
|
|
Oct 28
2023
|
Steven L. Hoerter President and CEO |
BUY
Grant, award, or other acquisition
|
Direct |
62,500
+50.0%
|
-
|
|
Oct 28
2023
|
Thomas Patrick Kelly Chief Financial Officer |
BUY
Grant, award, or other acquisition
|
Direct |
8,244
+11.2%
|
-
|
|
Oct 02
2023
|
Matthew L Sherman EVP & Chief Medical Officer |
SELL
Open market or private sale
|
Direct |
2,942
-3.36%
|
$35,304
$12.68 P/Share
|